Revenue during the quarter surged 110.57 percent to $19.24 million from $9.14 million in the previous year period. Gross margin for the quarter expanded 2061 basis points over the previous year period to 85.39 percent.

"This was a highly productive quarter for Arena. We continue to make significant progress focusing the company on our unpartnered clinical programs and building a high performing product development organization. We have expanded our clinical development and management team to facilitate better execution in a time and cost effective manner," said Amit Munshi, Arena's president and chief executive officer. "We are enthusiastic about our strategy to focus on our clinical stage programs, with a goal of developing first- or best-in-class assets with our three proprietary compounds which includes evaluating ways to expand their indications. In support of our programs, we have initiated efforts to communicate to the scientific community through an active outreach and publication strategy."